

Bioactive Compounds Identification of *Pleurotus platypus* and *Pleurotus eous* by GC-MS

*^aG. Sathyaprabha, ^bS. Kumaravel and ^cA. Panneerselvam

^aPG & Research Department of Microbiology, PRIST University, Department of Microbiology, Vallam, Thanjavur

^bDepartment of Food Quality and Testing, Indian Institute of Crop Processing Technology, Thanjavur

^cPG & Research Department of Botany and Microbiology, A.V.V.M sir Pushpam College, Poondi, Thanjavur

ABSTRACT

In this study, *Pleurotus platypus* and *Pleurotus eous* was subjected to identification of bioactive compounds by using Gas chromatography – Mass spectrum technique. These two organisms were extracted with 99% of ethanol. Extracted sample was injected, according to the retention time and peak formation the bioactive compounds are screened. In *Pleurotus platypus* Pyridine-3-carboxamide, 4-dimethylamino-N-(2, 4-difluorophenyl), Piperidin-4-carboxylic acid, Aspidofractinine-3-methanol, (2à, 3á, 5à), Indolizine, and 2-(4-methylphenyl)-. *Pleurotus eous* shows that Imidazolidine, 1, 3-dinitro, Phenol, 2-methyl-4-(1, 1, 3, 3-tetramethylbutyl), Aspidofractinine-3-methanol, (2à, 3á, 5à) and Squalene.

Key Words: Bioactive compounds, GC-MS, *Pleurotus eous* and *Pleurotus platypus*.

INTRODUCTION

Today, with the development of better technologies and greater realization of their nutrient values, mushrooms have occupied an important place in food in several parts of the world [1]. Researches on the nutritive value of edible mushrooms indicate that they may be regarded as healthy foods, even though they are deficient in calories and fat and consist of about 90% water [2, 3, and 4]. Mushrooms have been reported to be of therapeutic value, useful in preventing diseases such as hypertension, Hypercholesterolemia, cancer and also having antibacterial and antiviral properties. These functional characteristics are mainly due to their chemical composition [5, 6, 7 and 8].

The fruiting body of the mushroom is also a potential source of lignin and phenol degrading enzymes [9]. While from clinical viewpoint, [10] showed that *P. ostreatus* elicited hypocholesterolemic and antherogenesis inhibition functions in rabbits and rat courtesy of its mycelial secretory products. However, unlike the fruiting bodies of few other edible mushrooms such as *L. edodes*, *G. fondosa* and *G. lucidium* known for exhibiting antibacterial and antifungal activity *in vitro*, there is lack of information on the microbicidal properties of *P. ostreatus* coupled with inadequate data on its phytochemistry. It is hypothesized that knowledge of the phytoconstituents of *P. ostreatus* would provide an insight into its biological functions beyond nutrition when consumed.

MATERIALS AND METHODS

25gm of smashed fresh *Pleurotus eous* and *Pleurotus platypus* sample was taken in a conical flask with 30ml of distilled alcohol and keep it for overnight soaking then filter the sample and concentrated the sample with help of nitrogen flushing. Filter the filtrate with sodium sulphate. 2ul of purely prepared sample was injected into the programme GC-MS instrument.

GC Programme

Column: Elite-5MS (5% Diphenyl / 95% Dimethyl poly siloxane), 30 x 0.25mm x 0.25µm df
Equipment: GC Clarus 500 Perkin Elmer, Carrier gas: 1ml per min, Split: 10:1, Detector: Mass detector Turbo mass gold-Perkin Elmer, Software: Turbomass 5.2, Sample injected: 2µl

Oven temperature Programme

110° C -2 min hold, Up to 200° C at the rate of 10 ° C/min-No hold, Up to 280 ° C at the rate of 5° C / min-9 min hold, Injector temperature 250° C, Total GC running time 36 min

MS Programme

Library used NIST Version-Year 2005, Inlet line temperature 200°C, Source temperature 200°C Electron energy:70 eV, Mass scan (m/z): 45-450, Solvent Delay: 0-2 min, Total MS running time: 36 min

RESULTS AND DISCUSSION

Identification of Components

Interpretation on mass spectrum GC-MS was conducted using the database of National Institute Standard and Technology (NIST) having more than 62,000 patterns. The spectrum of the unknown component was compared with the spectrum of the known components stored in the NIST library. The name, molecular weight and structure of the components of the test materials were ascertained. Table 1 & 2.

P. platypus and *P. eous* was subjected to GC-MS study for identification of medicinal properties, According to the results, the Phytocomponents are screened, and most of the medicinal properties are Pyridine-3-carboxamide, 4-dimethylamino-N-(2,4-difluorophenyl)-, Piperidin-4-carboxylic acid, Aspidofractinine-3-methanol, (2 α ,3 α ,5 α)-, 1H)Pyrrole-2-carboxaldehyde, 4-(trichloroacetyl)-, Indolizine, 2-(4-methylphenyl)- are present in *P. platypus*. In *P. eous* Imidazolidine, 1,3-dinitro, Phenol, 2-methyl-4-(1,1,3,3-tetramethylbutyl), Aspidofractinine-3-

methanol, (2 α ,3 α ,5 α)- and Squalene are presented. The anticancer properties contain Phytochemical compounds were screened in the GC-MS which shows the high activity, other Phytocomponents were showed in the chromatogram.

Table: 1 Components identified in the *Pleurotus platypus* Sample [GC-MS Study]

No.	RT	Name of the compound	Molecular Formula	MW	Peak Area %
1.	7.17	DL-Alanine, N-benzoyl-N-(3-chloro-4-fluorophenyl)-, methyl ester	C ₁₇ H ₁₅ ClFNO ₃	335	0.76
2.	7.44	(1H)Pyrrole-2-carboxaldehyde, 4-(trichloroacetyl)-	C ₇ H ₄ Cl ₃ NO ₂	239	0.76
3.	7.96	2-Amino-4-hydroxy-6,7,8-trimethylpteridine	C ₉ H ₁₁ N ₅ O	205	3.80
4.	12.49	Benzoic acid 1-methoxy-1H-tetrazol-5-ylmethyl ester	C ₁₀ H ₁₀ N ₄ O ₃	234	0.76
5.	13.06	Pyridine-3-carboxamide, 4-dimethylamino-N-(2,4-difluorophenyl)-	C ₁₄ H ₁₃ F ₂ N ₃ O	277	74.14
6.	13.45	β -Ethyl aspartate	C ₆ H ₁₁ NO ₄	161	2.28
7.	18.80	Piperidin-4-carboxylic acid	C ₆ H ₁₁ NO ₂	129	1.52
8.	20.82	Aspidofractinine-3-methanol, (2 α ,3 α ,5 α)-	C ₂₀ H ₂₆ N ₂ O	310	4.94
9.	24.67	Indolizine, 2-(4-methylphenyl)-	C ₁₅ H ₁₃ N	207	11.03


GC-MS Chromatogram of *Pleurotus platypus*

Pleurotus platypus

IICPT, Thanjavur, 8-MAR-2011 + 14:32:15

GC-MS Analysis170

Scan EI+




GC-MS Chromatogram of *Pleurotus eous*

Pleurotus eous

IICPT, Thanjavur, 8-MAR-2011 + 15:13:30

GC-MS Analysis171

Scan EI+



CONCLUSION

In this study, *Pleurotus platypus* and *Pleurotus eous* were extracted with pure ethanol and subjected to screening of bioactive compounds by Gas Chromatography-Mass Spectrum technique, according to the results various active compounds are presented in *Pleurotus platypus* when compared with *Pleurotus eous*. The active compounds are Pyridine-3-carboxamide, 4-dimethylamino-N-(2, 4-difluorophenyl)-, Piperidin-4-carboxylic acid, Aspidofractinine-3-

methanol, (2à, 3á, 5à)-, 1H) Pyrrole-2-carboxaldehyde, 4-(trichloroacetyl)-, Indolizine, 2-(4-methylphenyl)- are present in *P.platypus*. In *P.eous* Imidazolidine, 1, 3-dinitro, Phenol, 2-methyl-4-(1, 1, 3, 3-tetramethylbutyl), Aspidofractinine-3-methanol, (2à, 3á, 5à) - and Squalene

Table: 2 Components identified in the *Pleurotus eous* Sample [GC-MS Study]

No.	RT	Name of the compound	Molecular Formula	MW	Peak Area %
1.	7.96	5-(4-Hexyloxybenzoyloxy)-2-(4-nitrophenyl) pyrimidine	C ₂₃ H ₂₃ N ₃ O ₅	421	0.01
2.	10.15	Imidazolidine, 1,3-dinitro-	C ₃ H ₆ N ₄ O ₄	162	0.02
3.	12.64	dl-Alanine	C ₃ H ₇ NO ₂	89	0.01
4.	16.89	Phenol, 2-methyl-4-(1,1,3,3-tetramethylbutyl)-	C ₁₅ H ₂₄ O	220	0.07
5.	17.51	1H-Tetrazol-5-amine	CH ₃ N ₅	85	0.02
6.	20.90	Aspidofractinine-3-methanol, (2à,3á,5à)-	C ₂₀ H ₂₆ N ₂ O	310	99.83
7.	24.66	Squalene	C ₃₀ H ₅₀	410	0.05

Acknowledgement

I thank to My Guide Dr. A. Panneerselvam, A.V.V.M. Sri Pushpam College, Co-Guide Dr. P. Prabhakaran, PRIST University-Vallam, Dr.Usha K.N.Govts. Arts and Science women's college- Thanjavur. The Director, IICPT-Thanjavur, Dr.P. Karthikeyan, Scientist PRIST University, Shri.S.Kumaravel, Scientist, IICPT- Thanjavur and Mr. R. Paranthaman, Technical Assistant, IICPT, Thanjavur for helping me to carry out my research work and to publish this article.

REFERENCES

- [1] Hafiz F.M, Begum S, Parveen Z Nessa and A.K. Azad, *Pakistan J. Nutr.*, **2003**, 2: 279–82
- [2] Nylen, B., *Vara Matsvampar*. Naturoch. Kultur/LTs forlag, **1985**,
- [3] Manzi, P., L. Gambelli, S. Marconi, V. Vivandti and L. Pizzoferrato, *Food Chem.*, **1999**, 65: 477–82
- [4] Sanmee, R., B. Dell, P. Lumyong, K. Izumori and S. Lumyong, *Food Chem.*, **2003**, 82: 527–32
- [5] Cochran, K.W., Medicinal effects. In: Chang, S.T. and W. Hayes (eds.), *The Biology and Cultivation of Edible Mushrooms*, Academic Press, New York, **1978**, Pp: 169–87.
- [6] Chovot, V., L. Opletal, L. Jahodar, A.V. Patel, C.G. Dacke and G. Blunden, *Phytochem.*, **1997**, 45: 1669–71
- [7] Gunde-Cimerman, N., *Int. J. Med. Mush.*, **1999**, 1: 69–80
- [8] Manzi, P., A. Aguzzi and L. Pizzoferrato, *Food Chem.*, **2001**, 73: 321–5
- [9] Fountoulakis MS, Dokianakis SN, Kornaros ME, Aggelis GG, Lyberatos G, *Water Res.*, **2002**, 36: 4735-4744.
- [10] Bobek P. Galbavy S, Hypocholesteremic and antiatherogenic effect of oyster mushroom (*Pleurotus ostreatus*) in rabbits *Nahrung* **1999**, 43: 339–342.